PET/CT imaging in cancer: current applications and future directions (Q38221774)

31 August 2017

PET/CT imaging in cancer: current applications and future directions (English)

1 reference

31 August 2017

Michael D Farwell

1

1 reference

31 August 2017

Daniel A Pryma

series ordinal

2

1 reference

31 August 2017

David A Mankoff

series ordinal

3

1 reference

31 August 2017

language of work or name

English

0 references

publication date

19 June 2014

1 reference

31 August 2017

1 reference

31 August 2017

120

1 reference

31 August 2017

22

1 reference

31 August 2017

3433-3445

1 reference

Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy

31 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: Validation of method

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Anatomy of SUV. Standardized uptake value

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

True tracers: comparing FDG with glucose and FLT with thymidine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Impact of 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohorts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Current and future uses of positron emission tomography in breast cancer imaging

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

FDG PET and PET/CT imaging in lymphoma and melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Positron emission tomography in urological oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Positron emission tomography scanning in the evaluation of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Imaging of tumor glucose utilization with positron emission tomography

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

[18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

The lessons of GIST--PET and PET/CT: a new paradigm for imaging

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Metabolic flare: indicator of hormone responsiveness in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

The role of PET in monitoring therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Positron emission tomography as an imaging biomarker

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Neuroimaging of juvenile pilocytic astrocytomas: an enigma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Diagnostic value of FDG PET and salivary gland scintigraphy for parotid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Monitoring tumor response to therapy with 18F-FLT PET.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

PET imaging of cellular proliferation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Imaging proliferation in vivo with [F-18]FLT and positron emission tomography.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Radiosynthesis of 3'-deoxy-3'-[(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

The role of human nucleoside transporters in uptake of 3'-deoxy-3'-fluorothymidine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

[18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Early Response Assessment Using 3'-Deoxy-3'-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

PET imaging with [18F]3'-deoxy-3'-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Imaging of cell proliferation: status and prospects

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Evaluation of 2'-deoxy-2'-[18F]fluoro-5-methyl-1-beta-L: -arabinofuranosyluracil ([18F]-L: -FMAU) as a PET imaging agent for cellular proliferation: comparison with [18F]-D: -FMAU and [18F]FLT.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Development of (18)F-labeled PET probes for imaging cell proliferation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Assessment of cellular proliferation in tumors by PET using 18F-ISO-1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Hypoxia in cancer: significance and impact on clinical outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Tumor hypoxia imaging.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Nitric oxide-mediated regulation of chemosensitivity in cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Imaging hypoxia and angiogenesis in tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation O

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Cancer and radiation therapy: current advances and future directions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Prognostic value of 99mTc-HYNIC annexin-V imaging in squamous cell carcinoma of the head and neck.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

18F-labelled annexin V: a PET tracer for apoptosis imaging

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

18F-ICMT-11, a caspase-3-specific PET tracer for apoptosis: biodistribution and radiation dosimetry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Biodistribution and radiation dosimetry of 18F-CP-18, a potential apoptosis imaging agent, as determined from PET/CT scans in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Assessment of response of brain metastases to radiotherapy by PET imaging of apoptosis with ¹⁸F-ML-10.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.28860

1 reference

7 January 2021

Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Diagnosis of maxillofacial tumor with L-3-[18f]-fluoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Assessment of therapy response in lung cancer with ¹⁸F-α-methyl tyrosine PET.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

18F-FET PET/CT in advanced head and neck squamous cell carcinoma: an intra-individual comparison with 18F-FDG PET/CT.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Brain tumour imaging with PET: a comparison between [ 18 F]fluorodopa and [ 11 C]methionine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Initial experience with the radiotracer anti-1-amino-3-[18F]Fluorocyclobutane-1-carboxylic acid (anti-[ 18F]FACBC) with PET in renal carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

New targeted therapies in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Probes for non-invasive matrix metalloproteinase-targeted imaging with PET and SPECT.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28860

7 January 2021

Identifiers

DOI

10.1002/CNCR.28860

1 reference

31 August 2017

1 reference